Copyright
©The Author(s) 2022.
World J Clin Cases. Jun 26, 2022; 10(18): 6091-6104
Published online Jun 26, 2022. doi: 10.12998/wjcc.v10.i18.6091
Published online Jun 26, 2022. doi: 10.12998/wjcc.v10.i18.6091
Figure 5 Forest plot for comparisons of the rate of adverse events for adalimumab and infliximab.
A: Overall adverse events; B: Severe adverse events; C: Opportunistic infection. ADA: Adalimumab; IFX: Infliximab; CI: Confidence interval.
- Citation: Yang HH, Huang Y, Zhou XC, Wang RN. Efficacy and safety of adalimumab in comparison to infliximab for Crohn's disease: A systematic review and meta-analysis. World J Clin Cases 2022; 10(18): 6091-6104
- URL: https://www.wjgnet.com/2307-8960/full/v10/i18/6091.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v10.i18.6091